 |
|
|
| |
The Initial Phase I Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK3640254, a Next-Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects
|
| |
| |
20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral
Drugs. May 14-16, 2019. Noordwijk, the Netherlands
Reported by Jules Levin
Samit R. Joshi,1 Disala Fernando,2 Stephanie Igwe,2 Litza McKenzie,3 Anu S. Krishnatry,4 Fiona Halliday,5 Joyce Zhan,4 Mark Johnson,6 Geraldine Ferron-Brady,4 Max Lataillade,1 Sherene Min,6 on behalf of the GSK3640254 Study Team
|
| |
|
|
|
|
|
